Multidrug resistant tuberculosis treatment in India-Reference-Cited by-同舟云学术

Multidrug resistant tuberculosis treatment in India

Published:2015 Issue:3 Volume:9 Page:156-164
ISSN:1881-7831
Container-title:Drug Discoveries & Therapeutics
language:en
Short-container-title:DD&T

Author:

Prasad Rajendra¹,Gupta Nikhil²,Balasubramanian Viswesvaran¹,Singh Abhijeet¹

Affiliation:

1. Department of Pulmonary Medicine, Vallabhbhai Patel Chest Institute, University of Delhi

2. Department of Medicine, Era’s Medical College

Publisher

International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)

Subject

Pharmacology (medical),General Pharmacology, Toxicology and Pharmaceutics,General Medicine

Reference55 articles.

1. 1. Multi-drug resistant tuberculosis. ICMR. 1999; 29:105-114.

2. 2. Prasad R, Singh A, Srivastava R, Kushwaha R, Garg R, Hosmane G B, Jain A. Adverse drug reaction in treatment of multidrug resistant tuberculosis. Chest. 2013; 144:390A.

3. 3. Prasad R, Verma S K, Sahai S, Kumar S, Jain A. Efficacy and safety of kanamycin, ethionamide, PAS, and cycloserine in multidrug resistant pulmonary tuberculosis patients. Ind J Chest Dis Allied Sci. 2006; 48:183-186.

4. 4. Tsukamura M, Mizuno S. Cross-resistant relationships among the aminoglycoside antibiotics in Mycobacterium tuberculosis. J Gen Microbiol. 1975; 88:269-274.

5. 5. Venkataraman P, Paramasivan CN, Prabhakar R. In vitro activity of rifampicin, rifapentine and rifabutin against south Indian isolates of Mycobacteirum tuberculosis. Ind J Tub. 1993; 40:171-175.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent and New Strategies for Extensively-Drug Resistant Tuberculosis;Mediterranean Journal of Infection Microbes and Antimicrobials;2019-04-09

2. The Potential Impact of Border Security Upon Prevalence of Infectious Disease;Disaster Medicine and Public Health Preparedness;2018-03-15

3. Population pharmacokinetics of moxifloxacin, cycloserine, p -aminosalicylic acid and kanamycin for the treatment of multi-drug-resistant tuberculosis;International Journal of Antimicrobial Agents;2017-06